CTOs on the Move

Pacific Homecare Services

www.phrespite.com

 
Pacific Homecare Services is a Stockton, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 1K-5K
  • Annual Revenue: $1-10 Million
  • www.phrespite.com
  • 1919 Grand Canal Blvd Ste c3
    Stockton, CA USA 95207
  • Phone: 209.956.2532

Executives

Name Title Contact Details

Similar Companies

Accelovance Inc.

Accelovance Inc. is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Rockville, MD. To find more information about Accelovance Inc., please visit www.accelovance.com

BDF

BDF is a Morristown, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

ClaimPay

Claimpay is a healthcare billing company that combines smart technology with billing expertise to manage a practices entire revenue process.

PreclinPharma

PreclinPharma is a Englewood, NJ-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Accord BioPharma

Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.